---
title: “FDA Gives Nod to Mirvetuximab Soravtansine”, Cancer Discovery (2023)
description: "Link to Publication: [https://aacrjournals.org/cancerdiscovery/article-abstract/13/1/8/712680/FDA-Gives-Nod-to-Mirvetuximab-SoravtansineFDA](https://aacrjournals.org/cancerdiscovery/article-abstract/13/1/8/712680/FDA-Gives-Nod-to-Mirvetuximab-SoravtansineFDA) Abstract: The FDA has granted accelerated approval to mirvetuximab soravtansine to treat patients with folate receptor alpha (FRα)–positive, platinum-resistant epithelial ovarian, primary peritoneal, and fallopian tube cancers. The FDA also approved the VENTANA FOLR1 (FOLR-2.1) RxDx…"
url: "https://eyedrugtox.com/docs/fda-gives-nod-to-mirvetuximab-soravtansine-cancer-discovery-2023/"
updated: "2023-03-17"
category: Elahere
---

# “FDA Gives Nod to Mirvetuximab Soravtansine”, Cancer Discovery (2023)

Link to Publication:

[https://aacrjournals.org/cancerdiscovery/article-abstract/13/1/8/712680/FDA-Gives-Nod-to-Mirvetuximab-SoravtansineFDA](https://aacrjournals.org/cancerdiscovery/article-abstract/13/1/8/712680/FDA-Gives-Nod-to-Mirvetuximab-SoravtansineFDA)

Abstract: The FDA has granted accelerated approval to mirvetuximab soravtansine to treat patients with folate receptor alpha (FRα)–positive, platinum-resistant epithelial ovarian, primary peritoneal, and fallopian tube cancers. The FDA also approved the VENTANA FOLR1 (FOLR-2.1) RxDx Assay companion diagnostic device, which detects the FRα protein and could determine which patients will likely respond to the antibody–drug conjugate.